Second-generation H1 antagonists, such as loratadine and fexofenadine ... antihistamines are more useful for allergic rhinitis or urticaria than for cough and cold symptoms.

Urticaria affects both children and adults, with chronic cases more common in women, and often presents in emergency or dermatology settings. Conditions like vasculitic urticaria, erythema ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with chronic spontaneous urticaria. The approval is for patients 12 years and ...

Rilzabrutinib, an oral inhibitor of Bruton tyrosine kinase (BTK), demonstrated a rapid and substantial alleviation of symptoms in patients with chronic spontaneous urticaria (CSU) unresponsive to ...

In two clinical studies, Dupixent showed reductions in itch severity and urticaria activity at 24 weeks, as well as an increased likelihood of well-controlled disease or complete response at 24 ...

Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic spontaneous urticaria (“CSU”) in adults and adolescents aged 12 years ...

some patients may have concomitant chronic inducible urticaria. For type IIb disease, patients are more often women, exhibit frequent comorbid autoimmune diseases, have low total IgE levels ...

Sanofi and Regeneron's fully human monoclonal antibody Dupixent (dupilumab) has gained approval from the US Food and Drug Administration (FDA) for treating chronic spontaneous urticaria (CSU ...